Viral “Socializing” Holds Key to Overcoming Antiviral Resistance, New UW Study Finds
A counterintuitive finding from University of Washington researchers suggests that promoting interaction between viruses, rather than aggressively eliminating them, may be a more effective strategy for combating antiviral resistance. Teh findings,published this week in Nature Ecology & Evolution,could reshape approaches to antiviral drug progress and dosing.
The study centers on poliovirus and the investigational antiviral drug, pocapavir. While promising in laboratory settings, pocapavir has shown limited success in clinical trials, prompting scientists to investigate the underlying reasons. Researchers discovered that the drug’s effectiveness hinges on a surprising phenomenon: the interaction between susceptible and resistant strains of the virus within the same cell.
the Paradox of Potency
“The key insight in our paper is counterintuitive,” explained alison Feder, an assistant professor of genome sciences and a Freeman Hrabowski Scholar at the Howard Hughes Medical Institute. “pocapavir’s success depends on viruses interacting inside the same cell. But when treatment reduces the viral population as intended, those interactions can unintentionally vanish.”
The team, led by Ph.D. student Alexander J. Robertson in the Molecular & Cellular Biology program at the University of Washington, developed a mathematical model to explain this dynamic.Initially, pocapavir works by allowing susceptible polioviruses to sensitize their resistant counterparts, making them more vulnerable to the drug. However, as the drug reduces the overall viral load, the density of viruses within cells decreases.
This lower density means fewer opportunities for susceptible and resistant viruses to co-infect the same cell, effectively eliminating the sensitizing effect. Consequently, resistant strains are able to thrive and evolve, ultimately leading to widespread drug resistance.
Did you know?-Viruses can compete, cooperate, and even share genomic resources, a dynamic researchers have likened to a “microbial potluck.”
A “Microbial Potluck” and the Evolution of Resistance
The research highlights the complex social lives of viruses, even though it remains debated whether they are truly “living.” These entities can compete, cooperate, and share genomic resources – a dynamic the researchers likened to a “microbial potluck.” These collective efforts significantly influence their susceptibility to treatments.
“I study the evolution of antimicrobial resistance through mechanisms which require interaction between microbes,” Robertson stated.
The UW team’s work builds on a growing understanding that viruses don’t exist in isolation. Examining their communal responses to challenges like antiviral drugs is crucial for developing more effective therapies.
Pro tip:-Reducing the potency of an antiviral drug, by lowering the dose, can sometimes improve its efficacy by maintaining a sufficient population of susceptible viruses.
Lowering the Dose, Increasing the Possibility
surprisingly, the study revealed that reducing the potency of pocapavir could actually improve its efficacy. By lowering the dose, researchers were able to maintain a sufficient population of susceptible viruses to continue sensitizing the resistant ones. This approach, while seemingly counterintuitive, allowed for continued interaction between strains, hindering the evolution of widespread resistance.
The findings suggest a trade-off for antivirals that rely on viral interaction.A strong, rapid reduction in viral load can quickly clear an infection but may inadvertently promote resistance.A gentler approach, while slower, could preserve the necessary interactions to limit the emergence of resistant strains and prevent rebounds.
“By promoting social interactions in viruses in this way, a less potent drug may ironically improve its future utility,” the authors noted.
Reader question:-Are these findings promptly applicable to clinical practice? The research team emphasizes that these findings are not yet a clinical recommendation, but they open the door to exploring novel antiviral dosing strategies.
The research was funded by the National Institutes of Health (T32-GM136534-02) and the Environmental Biology Division at the National Science Foundation (2142718). The team, which also included senior authors Ben Kerr, whose lab combines math, computer simulation, and experiments to study ecology and evolutionary biology, emphasized that these findings are not yet a clinical recommendation. However, they open the door to exploring novel antiviral dosing strategies that enhance the opportunity for co-infection, ultimately limiting resistance and improving treatment outcomes.
